' INTRODUCTION
Worldwide, over 1 million breast cancer cases are diagnosed each year, accounting for nearly a quarter of all cancer incidences in women. Approximately 400 000 deaths are reported annually that can be directly attributed to this disease. 1 The majority of invasive breast cancers, approximately 80%, are generally classified as invasive ductal carcinomas (IDC), a malignant neoplasm that is initiated in the ductal lobes and then invades the surrounding breast tissue.
Tumor growth, invasion and metastasis are dependent on access to the blood supply. Blood vessel formation in tumors occurs by a variety of mechanisms including angiogenesis, a complex process by which existing blood vessels sprout and develop new vessels. 2À4 Angiogenesis is regulated by a balance of pro-and antiangiogenic factors and is normally restricted to developing or reproductive tissues and to wound repair. However, in tumors, angiogenesis is triggered by factors such as vascular endothelial growth factor (VEGF) that are secreted by hypoxic tumors and surrounding stromal cells, as well as by inflammatory cells recruited to the tumor site.
2,5À7 The process of tumor angiogenesis results in vessels that are structurally and functionally abnormal. 5 Relative to the normal vasculature, tumor vessels are leaky, tortuous, excessively branched and have many dead end sacs. Thus, despite the extensive vascularization observed in many tumors, perfusion is poor and a hypoxic environment is perpetuated within regions of the tumor. 5 Proteomic studies of breast cancer abound but relatively few have focused on either the tumor microenvironment 8, 9 or the tumor microvasculature. 10À12 Since the local environment often dictates protein expression in vessels, it is important to analyze the proteomes of vessels in the tumor tissue itself. This poses a challenge as vessels comprise a relatively small part of any tissue, even highly vascularized tumors. Therefore, a vessel enrichment/ isolation strategy is required prior to protein extraction and analysis.
Laser capture microdissection (LCM) can be used to selectively isolate defined cellular features from tissues. 13 For example, several groups have used LCM to isolate tumor cells, epithelial cells, or metastases from clinical breast samples. 9, 14, 15 For
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KEYWORDS: cancer, vessels, laser capture microdissection, invasive ductal carcinoma isolating microvessels, LCM has been used in a number of microarray-based genomic studies. Pen et al. compared the transcriptome of LCM-captured-vessels from malignant glioblastoma multiforme and nonmalignant brain tumors and found that 42 genes were differentially expressed. 16 Bhati et al. compared the transcriptome of LCM-captured vessels from luminal-A breast cancers and normal breast tissues. 17 They identified over 1176 differentially expressed genes, many of which code for extracellular matrix proteins.
There are still only a few examples of proteomic analyses being performed on LCM-captured microvessels, with the majority of studies focusing on brain microvessels. 18 In our laboratory, ICAT-LC-MS was used to analyze protein expression in LCMcaptured microvessels from the brain of rats undergoing cerebral ischemia. 19 Over 3000 peptide pairs were detected and 55 proteins were found to be differentially expressed in ischemic vessels relative to normal. More recently, Lu et al. identified over 880 proteins from LCM-captured microvessels from mouse brain using 1D SDS-PAGE fractionation and LC-FTICR-MS/ MS analysis. 20 Mustafa et al. employed MALDI-FTMS to analyze tryptic digests of microvessels LCM-captured from 10 human glioblastoma samples and 10 normal brain samples. 11 Three proteins, fibronectin, colligin-2 and acidic calponin-3, were determined to be strongly up-regulated in glioblastoma vessels.
In this article, we present the results of a study that compared protein expression in microvessels isolated by LCM from IDC breast tumors and adjacent nonmalignant breast tissue from the same patient. This approach has the advantage of eliminating some of the inherent heterogeneity between individual patients 21, 22 and between different cell types present in the samples. A simple on-cap tryptic digestion procedure was developed to minimize issues arising from excessive sample manipulation postcapture. The resulting digests were analyzed by label-free LCÀMS(/MS) and differential expression analysis was performed using software developed in-house. To our knowledge, this is the first proteomic study to use laser capture microdissection to enrich microvessels from clinical breast tumor samples.
' METHODS

Materials
Clinical samples (10 frozen human breast tumor biospecimens and their matching adjacent nontumor control tissues) were provided by the Ontario Tumor Bank (OTB; Toronto, ON, Canada), which is funded by the Ontario Institute for Cancer Research. Specimens were selected using the following criteria: (1) Infiltrating Ductal Carcinoma (IDC) histology, (2) availability of nonmalignant adjacent breast tissue, (3) gender (female), (4) degree of vascularity, (5) patient age (between 35 and 65 years), and (6) availability of clinical patient data. Frozen tissue samples embedded in OCT were cut at À21°C into 8 μm serial sections using a cryotome (Leica CM1900, Richmond Hill, ON, Canada). Sections were mounted on Superfrost Plus microscope slides (Fisher Scientific, Ottawa, ON, Canada) and kept at À80°C until use. This study was approved by the OTB and National Research Council Human Ethics Committees. All human subjects provided a written, informed consent.
Laser Capture Microdissection
To visualize blood vessels, tissue sections were fixed in 75% ethanol, washed with water, and incubated for 3 min at RT with fluorescein-conjugated Ulex Europaeus Agglutinin I (UEA1, Vector Laboratories) diluted (1:20 or 1:100) in D-PBS (Wisent, Inc., St-Jean Baptiste, QC, Canada). The slide was washed in D-PBS (30 s), dehydrated in 75, 95, and 100% ethanol (30 s), delipidated in xylene (5 min), and air-dried. Blood vessels were captured on CapSure Macro LCM Caps (Molecular Devices, Downingtown, PA) using an Arcturus PixCellII Laser Capture Microdisection System with fluorescence viewing option. The microdissection laser was set to 7.5 μm spot size and 850 μs pulse duration. The power was adjusted to the lowest value possible to allow efficient capture (between 30 and 70 mW). For each patient, a total of 6000À10 000 shots from both nonmalignant and tumor tissue sections were captured on 3 to 6 caps. Caps were stored at À80°C until use.
Tryptic Digestion and Mass Spectrometry
Trypsin digestion was performed by placing between 25 and 30 μL of digestion solution (20 μg/mL trypsin in 50 mM ammonium bicarbonate/15% acetonitrile) per 1000 LCM shots directly on the cap membrane and incubating overnight at 37°C. Pooled tryptic digests were analyzed by nanoLCÀESIÀMS (20À40 μL per run). Quantification runs were performed on a Q-TOF Ultima mass spectrometer coupled to a NanoAcquity UPLC system (Waters, Milford, MA). Samples were loaded on a NanoAcquity symmetry C18 trap (Waters) and separated on a 10 cm Â 100 μm I.D. C18 column (Waters, 1.7 μm BEH130C18) at ∼250 nL/minute using a 68 min gradient: 0À45% solution B (100% ACN/0.1% formic acid) over 66 min and 45À95% B over 2 min. Ten minute washes in 40% B were followed by 20 min blank gradients between each sample to minimize carryover effects. Continuum MS spectra were acquired in the TOF-MS mode between m/z 400À2000 with an acquisition duration of 1 s. Under these conditions, the average peptide elutes over a time period of ∼20 s, allowing 15À20 spectra to be collected over the chromatographic peak. For technical replicates, the entire set of nonmalignant and tumor digests was analyzed using these same parameters three times on separate days. The volume of tryptic digest loaded in the second and third technical replicates was adjusted to even out sample loading based on the median intensity values of multiply charged ions (excluding keratin and trypsin ions present in a mock digest) in the first technical replicate.
Both automated and targeted nano-LCÀESIÀMS/MS were used for peptide identification. For the targeted analysis, peptides showing a visual change in expression between nonmalignant and tumor samples using MSight 23 were sequenced by MS/MS on the Q-TOF Ultima using an include list with a specified mass, charge, and time window, under identical chromatographic conditions as the quantification runs. MS/MS was set to trigger exclusively on ions contained in the include list with the following parameters: 3 MS/MS per scan, exclude after MS/MS for 10 s, survey intensity threshold = 15, peak detection window = 2.5 Da. The automated MS/MS analysis was performed on an LTQOrbitrap-XL mass spectrometer (Thermo) under similar chromatographic conditions with an MS scan at 60k resolution in the FTMS analyzer and data-dependent turbo MS/MS scans on the top 3 ions in the trap with dynamic exclusion (180 s). Peptides identified by both methods were manually aligned with the Q-TOF quantification runs using MSight, as previously described. 24 
Database Searches
All MS/MS spectra were assigned to peptide sequences using Mascot v2.2. For Q-TOF data, peaklists were generated using PeptideAuto within MassLynx 4.1 using these parameters:
Journal of Proteome Research ARTICLE smooth (window = 4, # = 2, mode = Savitzky Golay), centroid (min peak width at half height = 4, centroid top = 80%). The resulting peak lists were searched against the Homo sapiens Swissprot database (sprot_57.14, 20345 sequences; parameters: enzyme = trypsin; modifications = carbamidomethyl (C, fixed), oxidation (M, variable); peptide tolerance = 1.2 Da; fragment tolerance = 1.2 Da; 1 missed cleavage allowed). Decoy database searches were used to estimate the false positive identification rate at different Mascot scores as follows (Mascot score >50 = 1.1%; > 45 = 2.9%; > 40 = 8.9%). In addition, all Q-TOF peptide identifications were manually verified. No cysteine containing peptides were present in our final list, as expected based on our search parameters and our sample preparation protocol that eliminated reduction/alkylation.
Orbitrap data was converted to mzXML using Msconvert from the ProteoWizard version 2.0.1905 package (http://proteowizard.sourceforge.net/index.html) with the following parameters: ÀmzXML À32 Àfilter 'peakPicking true [2,3]'. MGF files were then generated from the mzXML file using MzXML2Search from the Trans Proteomics Pipeline project (TPP-4.3.1, http:// tools.proteomecenter.org/wiki/index.php?title=Software:TPP) and searched against the Homo sapiens Swiss-Prot database (sprot_57.8, 20401 sequences) using the same parameters described above. Search results were subsequently filtered to remove peptides with a delta mass >15 ppm or a score <40. Under these conditions, the false positive identification rate based on decoy database searches was 1.1%. Peptides with a score >50 had a false positive rate of ∼0.3%.
Quantification by LCÀMS and Statistical Analysis
Peptides identified by either the targeted or automated analysis were quantified using in house software, based on MatchRx. 25 For quantification, the mass of centroided ions within the Q-TOF quantitation MS runs was required to be within 40 ppm of the theoretical peptide mass. Within each patient, the peptide intensities between nonmalignant and tumor were normalized so that the median intensity of all multiply charged ions quantified in every MS runs was equal, after excluding ions identified as trypsin or keratin. Peptides present in multiple proteins were assigned to the protein with the most peptides identified. If two or more proteins match all assigned peptides, these accession numbers are listed in the table as an alternate identification. Protein intensities from each MS run were calculated by summing the intensities of all unique peptides derived from that protein. When calculating fold change between nonmalignant and tumor samples, proteins with intensity values only in tumor (i.e., not in nonmalignant) or only in nonmalignant were assigned a fold change of 8 (log 2 ratio of 3) or À8 (log 2 ratio of À3.0), respectively. To identify differentially expressed proteins, two statistical tests were employed for each protein, one to compare data from all nonmalignant tissues to all tumor tissues and another to look at the expression of each protein within a single patient. First, the average normalized intensity values for the 6 adjacent nonmalignant samples were compared to the average normalized intensity values for the 6 tumor samples using a paired two-tailed student t test in Microsoft Excel. Proteins were considered differentially expressed if p < 0.05 and the average fold-change between nonmalignant and tumor was >2. Second, to identify proteins that may be expressed in only a subset of tumors, individual paired t tests were performed for each patient by comparing the intensity values of the 3 technical repeats from nonmalignant and tumor using a paired student t test. If 2 or more patients (out of 6) had p < 0.05 and a fold-change >2, then this protein was also considered differentially expressed, regardless of the protein expression in the other samples (equivalent to p < 0.05, assuming a binomial distribution for a series of independent Bernoulli trials).
Immunofluorescence
Breast tissue sections were incubated in methanol for 10 min at RT, rinsed with 0.2 M PBS (pH 7.3)/0.1% Triton-X, and incubated in a universal blocking solution (Dako Diagnostic, Mississauga, ON, Canada) for 1 h at RT followed by incubation with a polyclonal sheep antihuman CD31 antibody ( 
Western Blot Analysis
Breast tissue sections were fixed and delipidated as described above for the lectin staining prior to LCM, but excluding the lectin. Proteins were extracted from the entire section by incubation with 150 μL of 1Â NuPage LDS sample buffer (Invitrogen) on ice for 20 min. Protein extracts were sonicated, centrifuged at 15 000Â g for 20 min to remove cellular debris, and quantified using the Bio-Rad DC Protein assay. Equal quantities of total protein were reduced using 50 mM DTT (Sigma), separated by SDS-PAGE, and transferred to PVDF membranes using standard protocols. Membranes were blocked with 5% milk in TBS-T (10 mM Tris, 150 mM NaCl, 0.5% Tween 20, pH 8.0), incubated with primary antibody, washed with TBS-T, incubated with HRP-labeled secondary antibody, and developed using ECL Plus Western Blotting Detection System (Amersham). The primary antibodies and dilutions used were: anti-TAGLN2 (Proteintech Group, 1:500), anti-L-plastin (Abcam, 1:1000), anti-SERPINH1 (MJS Biolynx, 1:67), anti-ARPC3 (Novus Biologicals, 1:100), and anti-ATP5B (3D5, Santa Cruz, 1:200).
Microarray Data and Survival Curve Analysis
Gene expression profiles and patient survival data for breast cancer data sets including data from 236, 295, and 286 patients Journal of Proteome Research ARTICLE were obtained from Miller et al., 26 Chang et al., 27 and Wang et al., 28 respectively. To evaluate the prognostic value of a set of genes based on the gene expression profiles and associated survival information of the tumor samples, we performed a KaplanÀMeier analysis by implementing the CoxÀMantel logrank test using R, a statistical computing language (http://www. r-project.org/), as described previously. 29, 30 ' RESULTS AND DISCUSSION
Isolation of Microvessels from IDC and Adjacent Nonmalignant Tissue by Laser Capture Microdissection
To search for vascular markers of invasive ductal carcinoma (IDC), we used laser capture microdissection (LCM) to enrich for blood vessels in patient-matched samples of IDC and adjacent nonmalignant tissue. Ten matched pairs were acquired through the Ontario Tumour Bank. However, due to particularly low levels of vascularization in 3 patient samples, vessels were only captured for 7 matched pairs. Clinical information, including pathological classification, for these 7 patients is provided in Supplementary Table 1 (Supporting Information). Microvessels were identified using fluorescein-labeled Ulex Europaeus Agglutinin I (UEA1), a lectin that specifically binds to fucose residues of glycoproteins or glycolipids on endothelial cells. 31, 32 Since UEA1 occasionally recognizes cells of epithelial origin as well, only labeled areas that had the characteristic morphology of vessels were captured. An example of an excised microvessel is shown in Figure 1A . In order to capture a comparable number of vascular cells from the nonmalignant and IDC tumor samples, the same number of laser shots was used for each patientmatched sample set. As expected, the IDC tumor samples were more highly vascularized and contained less fat deposits than the adjacent nonmalignant tissue.
Identification of Differentially Expressed Proteins in Microvessel-Enriched Fractions from IDC and Adjacent Nonmalignant Clinical Tissues
Proteins in the microdissected vessels were digested using a simplified protocol where trypsin solution containing 15% acetonitrile was incubated directly on the laser-captured microvessels (see Figure 1B) . When compared to more traditional sample preparation methods involving separate steps for solubilization and enzymatic digestion, this on-cap digestion method minimizes sample manipulation, lessens sample loss, and reduces keratin contamination. Similar to direct digestion in methanol solutions, 33 ,34 the use of this procedure also appears to enrich for extracellular and cell surface proteins relative to the very abundant, but less accessible, cytoskeletal proteins.
For quantification, each digest was analyzed three separate times by nanoLCÀMS on a Q-TOF instrument and the resulting peptide ions were quantified using a label-free method based on the number of ion counts under the LCÀMS peak. A mock digest without any captured tissue was also analyzed to enable the identification of contaminant ions originating from trypsin autocleavages and keratins. Initially, visual examination of the LCÀMS data was used to determine multiply charged ions that were differentially expressed between IDC and adjacent nonmalignant vessels. These ions of interest were then targeted for identification by MS/MS in subsequent runs using an include list. In addition, a limited number of samples were analyzed by automated LCÀMS/MS on a LTQ-Orbitrap instrument. These two MS/MS methods, followed by database searching using Mascot, resulted in the identification of 560 unique peptides, which could be assigned to 182 unique proteins. Of these proteins, 94 were identified by more than one peptide, while 88 were identified by a single peptide. Despite the low number of peptides identified for each protein, the false positive identification rate of the 182 identified proteins was estimated at only 1% using a decoy database search strategy. The peptide sequences identified for each protein, including m/z, z, Mascot scores, retention time, and delta mass values, are provided in Supplementary Table 2 (Supporting Information). The intensity values for each individual peptide, as well as summed intensity values for each protein, are also provided. The quantitative data was quite consistent between the three technical repeats; protein intensities had a median relative standard deviation of 18% with an interquartile range of 10À31%. Also, individual peptides belonging to the same protein generally showed similar expression patterns, with a median Pearson coefficient of correlation of 0.88 (quartile range: 0.68À0.96) for the average intensity values of the 14 samples (7 IDC tumor and 7 nonmalignant).
To visualize the protein expression data across individual patients, we generated a heat map of the log 2 ratio of protein intensity in the IDC tumor microvessel fractions relative to the nonmalignant tissue in each patient (Figure 2 ). In general, five of the seven patients showed similar patterns of expression, while two patients, A00299 and A00319, were quite different. These differences may reflect natural heterogeneity between individual tumors or they may result from other issues, such as misclassification of adjacent nonmalignant tissue or differences in tumor collection. In fact, during LCM capture, we noted that the nonmalignant and tumor samples from patient A00299 looked quite similar to each other. In this patient, both the nonmalignant and tumor sections looked more phenotypically "normal" À both had relatively low levels of vascularization and significant fat deposits. Based on the noted discrepancy in phenotype and the quantitative MS results, we have excluded patient A00299 from our statistical analysis. As can be seen in Figure 2 , the correlation between the other 5 patients is quite strong, especially considering the different clinical characteristics of the IDC tumors (see Supplementary Table 1 , Supporting Information). We believe that the design of our experiments, using patient-matched tissues and an enriched cell population, may contribute to this correlation.
Statistical analysis based on paired student t tests identified 126 proteins that were differentially expressed between microvessels isolated from IDC and from nonmalignant tissues. Of these, 86 proteins were more highly expressed in the tumor vessels and 40 were more highly expressed in the nonmalignant vessels. These two groups of proteins are listed in Tables 1 and 2 , respectively. Proteins that were highly expressed in tumor vessels fell into several major functional categories, including RNAbinding proteins, regulators of the actin cytoskeleton, extracellular matrix (ECM) proteins, protein chaperones, metabolic enzymes, signal transduction molecules, and regulators of vesicular trafficking. The proteins that are under-expressed in tumor vessels include metabolic enzymes and ECM proteins, but also contain a number of proteins involved in lipid and fatty acid metabolism, major blood proteins, and proteins involved in caveolae formation. The relatively high proportion of identified proteins that were differentially expressed reflects the experimental design, particularly the include-list guided MS/MS, which biased protein identification to peptides with an apparent change in abundance between IDC and nonmalignant samples.
Evaluation of Selected Proteins by Immunofluorescence and Western Blotting
Eight proteins that were identified as overexpressed in IDC vessels were selected for further validation by fluorescent immunohistochemistry (IHC) of the adjacent nonmalignant and IDC tissue sections. Since secreted and cell surface proteins make particularly promising targets for cancer diagnosis and therapy, we focused our IHC efforts on this subset of proteins. To determine expression levels in the vasculature, tissue sections from at least 3 different patients were fluorescently stained for the antigen of interest (in red), nuclei (Hoechst stain, in blue), and CD31 (in green), a marker of endothelial cells in blood vessels (Figure 3) . In both the nonmalignant and IDC tissue sections, seven of the eight proteins were expressed in all or some microvessels, as demonstrated by colocalization with CD31. Although the remaining protein, L-plastin (LCP1), did not show significant staining of the CD31-positive endothelial cells themselves, it was significantly up-regulated in perivascular cells surrounding the vessels (see Figure 3D) , likely explaining the presence of this protein in our microdissected samples.
In addition to expression associated with the vasculature, several proteins that we examined by IHC were also expressed in the mammary gland ducts, namely Transgelin 2, HSP90AB1, IQGAP1, and Clic-1. It is possible that these proteins are upregulated in the endothelial and pericytes/smooth muscle cells of the tumor vessels. However, since tumor cells are known to infiltrate into the vasculature, it is also possible that tumor cells originating from the ducts were captured by our LCM method. Thus, some of the proteins identified in our experiments may reflect increased expression in tumor cells, rather than exclusive markers of tumor vasculature. For example, IQGAP1 showed widespread expression in the tumor, but with very limited expression in the nonmalignant tissue. This finding is consistent Proteins that showed higher protein expression in tumor vessels than in vessels from adjacent nonmalignant tissue are displayed in red and lower expression is displayed in green. Samples and proteins were organized by hierarchical clustering using average linkage and Euclidean distance. The proteins are identified by their gene symbol as found in the Uniprot database. ). Several proteins, such as Biglycan, Serpin H1, Transgelin 2, and Clic-1 showed expression in both the CD31-positive endothelial cells and in perivascular cells surrounding the vessels. To identify the nature of these perivascular cells, the tissue sections were stained with antibodies against smooth muscle actin (SMA), a marker of pericytes/smooth muscle cells (SMCs). Pericytes/SMCs are known to interact closely with endothelial cells and play an important role in regulating blood vessel maturation and blood flow. As shown in Figure 4 , Biglycan, Serpin H1, and Transgelin 2 all colocalize with R-SMA in tumor tissues, suggesting that they are expressed in pericytes/SMCs. Although most tumor vessels were surrounded by a thick layer of SMA-positive cells, some vessels had a much smaller proportion of associated SMA-positive cells (see Figure 4C , right-most vessel). These may represent immature microvessels, which are often found in tumors. 36 To further validate our proteomic results, we performed Western blotting using whole tissue protein extracts from the nonmalignant and IDC tumor samples from 2 different patients for which we had sample remaining after our previous analyses, patients A00026 and A00554. As can be seen in Figure 5 , Serpin H1, Transgelin 2, Plastin-2/L-plastin, and ARPC3 are much more highly expressed in the tumor, confirming our mass spectrometry results which showed more than a 2.5 fold increase in the expression of these proteins. The bands for each of these three proteins are located at the expected molecular weight and show similar expression patterns for both patient samples. The anti-Transgelin-2 antibody recognized two distinct bands; the upper band is located at the predicted molecular weight of the intact protein (22 kDa), suggesting that the lower band may be a proteolytic cleavage product. Although the relative abundance of the two Transgelin-2 bands is different in the 2 patients analyzed, both bands are strongly up-regulated in the tumor samples of both patients. In contrast, ATP5B, a protein found to be similarly expressed in nonmalignant and IDC vessels in our mass spectrometry experiments, showed similar expression patterns in the nonmalignant and IDC tumor tissues.
Identification of a Prognostic Signature
To examine the potential prognostic power of the differentially expressed proteins identified in this study, we examined the correlation between the expression of these proteins and patient survival. Clinical information provided with the breast tumors analyzed in this study indicated that 2 of the 7 tumors used in our proteomic analysis were derived from patients who relapsed within 2 years of diagnosis (patient A00319: diagnosis 09/2005, deceased 06/2006 and patient A00342: diagnosis 10/2005, recurrence 2/2007). Since patients A00299 and A00319 did not correlate well with the others, these outlier samples were excluded from further analysis and we calculated the relative expression of each differentially expressed protein in the remaining "bad" outcome tumor (patient A00342) relative to the four "good" outcome tumors (patients A00310, A00026, A00554, and A00588). To do this, we first calculated the ratio (R1) of the expression of each protein in the IDC tumor tissue relative to the adjacent nonmalignant tissue for each patient. We then calculated the ratio (R2) of R1 of each protein for the "bad" outcome sample to the average R1 value of the 4 "good" outcome samples. Based on the data point distribution, we determined that if the R2 value of a protein was greater than 2.5 or less than 0.4, the protein appeared to be differentially modulated in "bad" and "good" tumors. A total of 29 proteins met these criteria; these proteins are underlined within Tables 1 and 2 and are also listed separately  in Supplementary Table 3 (Supporting Information). Given the extremely low sample numbers, this analysis is by nature quite speculative; thus, we were interested in exploring the predictive power of this set of 29 proteins in a larger data set. Unfortunately, there are no publicly available data sets that include protein expression information linked to patient survival data. Therefore, we used three publicly available mRNA microarray data sets containing data from 236, 295, and 286 patient samples.
26À28
Despite the relatively low correlation between mRNA and protein levels, the mRNA expression values of the 29 genes identified through analysis of our proteomic data showed significant predictive power for breast cancer prognosis ( Figure 6 ). This result suggests that the 29 protein set is a vascular prognostic signature that can be linked to patient outcome and also implies that at least some of these proteins may be involved in the regulation of specific tumor properties. The 29-protein set includes 17 proteins that were up-regulated in IDC tumors and 12 proteins were down-regulated. The up-regulated proteins include Biglycan, Clic-1, Serpin H1, and HSP90AB1 which were included in the immunohistochemistry analysis.
Differentially Expressed Proteins in IDC
Many proteins identified in this study have been previously associated with breast cancer, including Fibronectin, Periostin, 37 Tenascin C, 38 Versican, 39 and L-plastin. 40 Several proteins also have known roles in angiogenesis and endothelial cell biology, a Swiss-Prot accession number (additional accession numbers containing the same set of peptides are listed in brackets when applicable). b Underlined proteins belong to the 29-protein set used in the survival analysis.
c Mean and median fold change of the 6 patient samples. a Swiss-Prot accession number (additional accession numbers containing the same set of peptides are listed in brackets when applicable). b Underlined proteins belong to the 29-protein set used in the survival analysis.
c Mean and median fold change of the 6 patient samples.
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ARTICLE including Caldesmon, 41 Calponin-2, 42 Periostin, and Tenascin C. In the following sections, we will discuss several of the differentially expressed proteins identified in these experiments in the context of cancer biology and tumor angiogenesis.
A. Extracellular Proteins. Our data suggests that the extracellular matrix associated with vessels undergoes a remodelling in IDC. For example, we see a consistent decrease in the expression of ECM proteins that comprise the vascular basement membrane, a thin layer of proteins surrounding the endothelial cells that serves to attach the vessel to the surrounding connective tissue. Protein components of the basement membrane include Collagen IV, Laminin, Perlecan/HSPG2, and Prolargin, all of which were underexpressed in tumor vessels. This likely reflects abnormalities in the basement membrane structure and composition in tumor vessels. 43 This hypothesis is supported by the lower level of abundant serum proteins (i.e., albumin, immunoglobulins, and hemoglobins) found in the IDC tumor vessels, suggesting lowered blood perfusion in tumor microvessels compared with nonmalignant microvessels. Interestingly, this abnormal basement membrane may serve to facilitate tumor cell metastasis by allowing tumor cells to enter the vasculature.
Other protein changes associated with the ECM include the up-regulation of Transforming growth factor beta-induced protein ig-h3 (Beta ig-h3) and Biglycan, and the down-regulation of the three chains of Collagen VI. Interestingly, Beta ig-h3 protein has been shown to interact directly with Biglycan and Collagen VI forming a ternary complex and promoting collagen aggregation. 44 It is possible that the lower level of Collagen VI seen in our experiment may reflect a rearrangement of Collagen VI from a more soluble form in nonmalignant tissue, to a highly complexed, inaccessible form in tumor tissue. Serpin H1 may also play a role in remodelling the collagen fibers surrounding tumor vessels, since it has been shown to play a critical role in the proper folding and trafficking of collagen subunits. 45 Thrombospondin 1 (THBS1), a protein that we identified as overexpressed in tumor vessels, is generally thought to negatively regulate tumorigenesis and angiogenesis. 46 However, several groups have reported an increase in THBS1 mRNA and protein in breast carcinomas. It has been suggested that the antiangiogenic effects of THBS1 must be overcome in order for cells to become tumorigenic; however, the mechanism of this change is not entirely understood. Interestingly, our results suggest that IDC tumor vessels have decreased expression of CD36, a cellsurface receptor that plays a significant role in mediating the antiangiogenic effect of THBS1. To our knowledge, a downregulation of CD36 expression in tumor endothelial cells has not been proposed as a mechanism of THBS-1 resistance in tumors. Our data suggests that levels of CD36 may be a factor in this process.
Clic-1, a chloride channel, has not previously been reported as a marker of IDC or other breast carcinomas. However, recent proteomic studies have demonstrated that Clic-1 is overexpressed in other cancers that are associated with epithelial tissues, including gastric, 47 colorectal, 48 and nasopharyngeal 49 cancers. Our results suggest that Clic-1 is also expressed in the endothelial cells and pericytes/SMCs of the microvasculature in breast. In other cancers, the expression of Clic-1 has been shown to correlate with metastatic potential. 47, 50 Furthermore, the genetic knockout of another Clic family member, Clic-4, leads to angiogenic defects in mice 51 and Clic-1 regulates endothelial cell growth and migration in culture, 52 suggesting the expression of Clic-1 in tumor vasculature seen in our proteomic and IHC studies may play a role in regulating tumor angiogenesis.
B. Cytoskeletal Proteins. Cell migration is a cyclical process that is largely driven by the polymerization and depolymerization of the actin cytoskeleton by a tightly regulated process that integrates cellular signals to drive reorganization of actin microfilaments in a concerted manner. 53, 54 As might be expected, several of the cytoskeletal proteins found to be overexpressed in IDC vessels have been previously shown to be overexpressed in tumors by other groups. For example, IQGAP1 overexpression is linked to cell migration and invasion, at least partially through actin rearrangements mediated by the Arp2/3 complex. The expression of IQGAP in endothelial cells has also been linked to the regulation of angiogenesis. 55 The actinin proteins, Actinin-1 and Actinin-4, mediate the interaction between actin microfilaments with the cell membrane and, indirectly, to Collagen 12 alpha 1 in the extracellular matrix. 56 Other up-regulated proteins that regulate the actin cytoskeleton include myosin subunits that mediate contraction and cross-linking actin-binding proteins that bundle actin filaments, such as the Plastins, Calponin-2, and Filamin A.
More unexpectedly, a couple of cytoskeletal proteins that were found to be overexpressed in tumor vessels have been previously shown to be underexpressed in cancers. Profilin-1 has not only been shown to be downregulated in breast cancer tumors and cells, but also functions to negatively regulate cancer cell motility. 57, 58 Similarly, Calponin-2 is downregulated in prostate cancer cells where it has been shown to inhibit proliferation and migration. 59 Presumably, the upregulation of Profilin-1 and Calponin-2 that we saw in this study is linked to higher expression of these proteins in IDC tumor vessels than nonmalignant vessels. In fact, Calponin-2 has been recently shown to regulate vascular development, as demonstrated by defects in endothelial cell migration when Calponin-2 is knocked down in zebrafish embryos. 42 This suggests that Calponin-2 may positively regulate tumor angiogenesis, consistent with the higher expression observed in IDC tumors.
C. Translational Machinery and Protein Folding Proteins. A large number of up-regulated proteins identified in this study are RNA-binding proteins. These include several ribosomal proteins from the large 60S and small 40S subunits, as well as members of the ubiquitous heterogeneous nuclear ribonucleoprotein family, ILF2 (a subunit from the transcription factor, NFAT, that also binds RNA), the spliceosome RNA helicase BAT1, and eukaryotic translation initiation factor 4A-1. Several translation elongation factors were also up-regulated in tumor vessels. Interestingly, our data suggests that a large group of proteins, including these RNA binding proteins and elongation factors, as well as a number of heat shock proteins, appear to be coregulated. By comparing the protein intensities in the 7 nonmalignant and 7 IDC tumor samples, we found several groups of proteins that showed highly correlated expression patterns, as defined by a Pearson coefficient of correlation greater than 0.9 (data not shown). The largest group of coregulated proteins comprises the ribosomal proteins, elongation factors, RNA binding proteins, the heat shock proteins, and the N-glycosyltransferase subunits. The coregulation of these proteins involved in translation and protein folding suggests that protein expression is regulated at a post-transcriptional level. In fact, microarray data collected in parallel with this study revealed that many of the proteins that we observed to be strongly upregulated did not have a corresponding change in their mRNA transcript levels (data not shown, manuscript in preparation).
D. Proteins that May Be Derived from Nonvascular
Cells. A number of proteins found to be more highly expressed in the nonmalignant samples are associated with the regulation or metabolism of lipids and fatty acids. These proteins include Perilipin-1 and 4, Fatty acid binding protein 4, and Long-chain fatty-acid-CoA ligase 1. As expected in breast tissue, the adjacent nonmalignant samples contained large areas of fat deposits, while the tumor samples were generally more "solid". Thus, it is possible that these proteins are derived from adipocyte cells that were located near blood vessels and thus were captured during the microdissection. As mentioned above, several major components of serum were also more highly expressed in nonmalignant vessels, likely reflecting decreased blood flow in tumor vessels.
E. Differentially Expressed Proteins in IDC:
Proteins with Lesser-Known or Emerging Links to Breast Cancer. It is clear from the discussion above that a large number of Figure 5 . Evaluation of the expression of selected proteins in total protein extracted from two patient-matched IDC tumors and adjacent nonmalignant tissues by Western blot. Strong up-regulation of Serpin H1, Transgelin-2 (TAGLN2), L-plastin (LCP1), and Actin-related protein 2/3 complex subunit 3 (ARPC3) was seen in the IDC tumors from both patients. A Western blot against ATP5B, a protein that showed no difference in expression between tumor and adjacent nonmalignant tissues in our mass spectrometry data, was used as a loading control. Figure 6 . Survival curve analysis using a set of 29 proteins found to be differentially expressed between adjacent nonmalignant and IDC tumor vessels. Gene expression corresponding to the 29-protein set was used to categorize patients into high-risk or low-risk groups using three publicly available microarray studies from (A) Miller et al., 25 (B) Chang et al., 26 and (C) Wang et al. 27 containing data from 236, 295, and 286 patients respectively. The survival data corresponding to each group of patients in each data set is shown.
proteins that we found to be differentially expressed in microdissected vessels from IDC breast tumors and the adjacent nonmalignant tissue have been previously implicated in cancer progression and/or angiogenesis. This correlation with the published literature is reassuring and serves to validate the results found in this study. However, it is also interesting to note proteins that have not previously been strongly linked to cancer. These include proteins such as the carboxypeptidase AGBL1, the ADP/ATP translocase, Slc25A6, and the emp24 family member, TMED10. Roles in breast cancer are just emerging for other proteins. For example, a recent proteomics study identified Clic-1 as upregulated and Transgelin 2 as downregulated in a metastatic variant of a breast cancer cell line. 60 Other proteins mentioned above, such as beta Ig-h3, and Serpin H1, have been implicated in other types of cancer, but to our knowledge have not been previously linked to breast cancer. Our results suggest that these proteins may play an important role in the vasculature of invasive ductal carcinoma. However, further work will be required to determine the function of these proteins in the context of IDC progression and tumor angiogenesis.
' CONCLUSIONS Proteomic analysis of LCM isolated microvessels from IDC breast tumors and adjacent nonmalignant patient-matched tissues led to the identification of 126 differentially expressed proteins. The application of a survival curve analysis based on publically available microarray data sets highlighted several of these proteins as likely candidates for further follow-up functional experiments. For example, Serpin H1 was part of the 29-gene set that predicted patient survival and was shown by immunofluorescence to have an interesting expression pattern in perivascular cells, including pericytes/smooth muscle cells. However, given the imperfect correlation between mRNA and protein levels, we hypothesize that the survival curve analysis would be more highly predictive if we were able to use protein expression data rather than mRNA microarray data. As proteomic technologies advance to improve the depth and coverage in protein expression data sets, we anticipate that data from large numbers of well-characterized clinical samples will become available thereby facilitating this type of analysis. This will add yet another dimension to our understanding of the mechanisms that underlie breast tumor development.
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